美国总部位于罗利的 RedHill Biopharma 正在寻求第二种 COVID-19 治疗方法

发布日期:

罗利 – 红山生物制药 is another step closer to getting one of its potential treatments for COVID-19 tested.

The Israeli company, which has its U.S. headquarters and commercial operations in Raleigh, got the green light to provide its investigational drug, RHB-107 (upamostat, WX-671), for testing in non-clinical studies against the coronavirus.

It’s part of an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

RHB-107 是一种专有的、同类首创的口服蛋白酶抑制剂,用于治疗胰腺癌和炎症性胃肠道疾病。RedHill 称,它为癌症治疗提供了一种新的、无细胞毒性的方法。

该药物已在 10 项临床研究中对 300 多人进行了研究,其中包括两项针对肿瘤患者的已完成的 2 期研究和几项针对健康志愿者和肿瘤患者的 1 期研究。RedHill 表示,这些研究有助于确定 RHB-107 对人类的安全性和耐受性。

It will now be used for in vitro testing against COVID-19, which, if successful, could lead to testing in humans for treating the disease.

“RHB-107 is the second investigational drug that RedHill is evaluating for COVID-19, underscoring our commitment to the global efforts to develop a treatment for patients with this disease,” said Terry F. Plasse M.D., medical director at RedHill.

“This new agreement will facilitate pre-clinical evaluation of RHB-107 as a potential COVID-19 treatment.”

A SECOND POSSIBLE TREATMENT?

Separately, Red Hill is investigating another novel drug, opaganib​ (Yeliva, ABC294640), as a potential treatment for COVID-19.

Opaganib is a new first-in-class orally-administered sphingosine kinase-2 (SK2) inhibitor with anti-viral, anti-inflammatory and anticancer characteristics, according to RedHill. Originally developed by U.S.-based Apogee Biotechnology Corp., the drug targets oncology, inflammatory and gastrointestinal disorders. RedHill said the therapy has the potential to reduce lung inflammation and to lessen lung damage.

A compassionate use program for COVID-19 patients is currently underway in Israel.

“Several patients [have been] treated to date, with preliminary positive outcomes,” Red Hill said in its release. The firm is under discussions in other countries for similar compassionate use.

同时,该公司已向美国食品药品管理局提交了一份新药临床试验申请,以评估奥帕加尼在确诊为新冠肺炎并伴有肺炎的成年人身上的临床研究效果。

原文来源: WRAL 技术线